These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35405741)

  • 1. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
    Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
    Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.
    Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1.
    Noh JY; Lee IP; Han NR; Kim M; Min YK; Lee SY; Yun SH; Kim SI; Park T; Chung H; Park D; Lee CH
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):769-788. PubMed ID: 35843546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Microenvironment Responsive CD8
    Chen Q; Yin H; He J; Xie Y; Wang W; Xu H; Zhang L; Shi C; Yu J; Wu W; Liu L; Pu N; Lou W
    Adv Sci (Weinh); 2023 Nov; 10(33):e2302498. PubMed ID: 37867243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
    Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
    Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of AB680: A Potent and Selective Inhibitor of CD73.
    Lawson KV; Kalisiak J; Lindsey EA; Newcomb ET; Leleti MR; Debien L; Rosen BR; Miles DH; Sharif EU; Jeffrey JL; Tan JBL; Chen A; Zhao S; Xu G; Fu L; Jin L; Park TW; Berry W; Moschütz S; Scaletti E; Sträter N; Walker NP; Young SW; Walters MJ; Schindler U; Powers JP
    J Med Chem; 2020 Oct; 63(20):11448-11468. PubMed ID: 32614585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
    Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
    Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
    Vigano S; Alatzoglou D; Irving M; Ménétrier-Caux C; Caux C; Romero P; Coukos G
    Front Immunol; 2019; 10():925. PubMed ID: 31244820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
    Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway.
    Wurm M; Schaaf O; Reutner K; Ganesan R; Mostböck S; Pelster C; Böttcher J; de Andrade Pereira B; Taubert C; Alt I; Serna G; Auguste A; Stadermann KB; Delic D; Han F; Capdevila J; Nuciforo PG; Kroe-Barrett R; Adam PJ; Vogt AB; Hofmann I
    Mol Cancer Ther; 2021 Nov; 20(11):2250-2261. PubMed ID: 34482286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer.
    Zhou Q; Ding W; Qian Z; Zhu Q; Sun C; Yu Q; Tai Z; Xu K
    Mol Pharm; 2021 Nov; 18(11):4015-4028. PubMed ID: 34648293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.
    Liu S; Li D; Liu J; Wang H; Horecny I; Shen R; Zhang R; Wu H; Hu Q; Zhao P; Zhang F; Yan Y; Feng J; Zhuang L; Li J; Zhang L; Tao W
    Onco Targets Ther; 2021; 14():4561-4574. PubMed ID: 34466002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
    Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
    Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
    Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
    Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment.
    Deng Y; Chen Q; Yang X; Sun Y; Zhang B; Wei W; Deng S; Meng J; Hu Y; Wang Y; Zhang Z; Wen L; Huang F; Wan C; Yang K
    Theranostics; 2024; 14(3):1224-1240. PubMed ID: 38323313
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.
    Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X
    J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.